PolyPeptide Group AG/Fr. PPGN
PolyPeptide shares rose after AlphaValue/Baader Europe raised its price target, citing expectations of improved FY26 EBITDA margins.
12 hours ago·Lightyear AI
07:00
09:05
11:10
13:15
15:20
1D1W1MYTD1Y5YMAX
About PolyPeptide Group AG
PolyPeptide Group AG operates in the pharmaceutical industry, specializing in the development and manufacture of peptides for various applications. Headquartered in Zug, Switzerland, the company provides essential services and products for the pharmaceutical and biotechnology sectors, including custom peptide synthesis and generic peptide production. With a network of manufacturing facilities across Europe and the United States, PolyPeptide Group AG supports a global clientele. The company's strategic positioning is reinforced by its focus on innovation and quality, ensuring compliance with rigorous industry standards. PolyPeptide's competitive strength lies in its extensive expertise and capabilities in peptide synthesis, serving sectors ranging from therapeutic peptides to cosmetics.
Ticker
Fr. PPGN
Sector
Primary listing
XSWX
Employees
1,440
Headquarters
Baar, Switzerland
Website
PPGN Metrics
BasicAdvanced
CHF 1.1bn
-
-CHF 0.59
1.03
-
Price and volume
Market cap
CHF 1.1bn
Beta
1.03
52-week high
CHF 41.70
52-week low
CHF 19.62
Average daily volume
59k
Financial strength
Current ratio
1.742
Quick ratio
0.866
Long term debt to equity
39.474
Total debt to equity
41.504
Interest coverage (TTM)
0.49%
Profitability
EBITDA (TTM)
35.096
Gross margin (TTM)
16.77%
Net profit margin (TTM)
-5.44%
Operating margin (TTM)
2.18%
Effective tax rate (TTM)
-5.54%
Revenue per employee (TTM)
CHF 248,720
Management effectiveness
Return on assets (TTM)
0.67%
Return on equity (TTM)
-6.07%
Valuation
Price to revenue (TTM)
3.086
Price to book
3.26
Price to tangible book (TTM)
3.4
Price to free cash flow (TTM)
-38.275
Free cash flow yield (TTM)
-2.61%
Free cash flow per share (TTM)
-0.877
Growth
Revenue change (TTM)
15.60%
Earnings per share change (TTM)
8.15%
3-year revenue growth (CAGR)
11.48%
3-year earnings per share growth (CAGR)
39.67%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs